Back to top

Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)

In a report released on August 7, Rajan Sharma from Goldman Sachs maintained a Buy rating on Genmab A/S, with a price target of $33.50. The company...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Genmab A/S Sponsored ADR (GMAB)